For the treatment of these luminal BC patients, endocrine therapies including selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs) and aromatase inhibitors are highly effective through the disruption of receptor binding or estrogen deprivation (Figure 1). This evidence concerns the gene CYP19A1 and breast cancer.